Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine

G. N. Hortobagyi, H. Y. Yap, C. L. Wiseman, G. R. Blumenschein, A. U. Buzdar, S. S. Legha, J. U. Gutterman, Evan M Hersh, G. P. Bodey

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Moderate doses of methotrexate and L-asparaginase were added to standard doses of 5-fluorouracil, Adriamycin, and cyclophosphamide in an attempt to improve the overall response rate and survival following chemotherapy. In addition, nonspecific immunotherapy with either Corynebacterium parvum or Pseudomonas vaccine was integrated into this prospective randomized clinical trial. The overall toxicity (degree of granulocytopenia and thrombocytopenia, length of myelosuppression, and incidence of myelosuppression-related infection and infectious deaths) increased considerably and led to the termination of patient accrual. The incidence of stomatitis and diarrhea was also increased with the addition of methotrexate and L-asparaginase, and apparently was potentiated by the addition of Pseudomonas vaccine to this five-drug combination.

Original languageEnglish (US)
Pages (from-to)157-159
Number of pages3
JournalCancer Treatment Reports
Volume64
Issue number1
StatePublished - 1980
Externally publishedYes

Fingerprint

Pseudomonas Vaccines
Asparaginase
Methotrexate
Fluorouracil
Doxorubicin
Cyclophosphamide
Breast Neoplasms
Stomatitis
Agranulocytosis
Incidence
Drug Combinations
Thrombocytopenia
Immunotherapy
Diarrhea
Survival Rate
Randomized Controlled Trials
Drug Therapy
Infection
Corynebacterium parvum vaccine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hortobagyi, G. N., Yap, H. Y., Wiseman, C. L., Blumenschein, G. R., Buzdar, A. U., Legha, S. S., ... Bodey, G. P. (1980). Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine. Cancer Treatment Reports, 64(1), 157-159.

Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine. / Hortobagyi, G. N.; Yap, H. Y.; Wiseman, C. L.; Blumenschein, G. R.; Buzdar, A. U.; Legha, S. S.; Gutterman, J. U.; Hersh, Evan M; Bodey, G. P.

In: Cancer Treatment Reports, Vol. 64, No. 1, 1980, p. 157-159.

Research output: Contribution to journalArticle

Hortobagyi, GN, Yap, HY, Wiseman, CL, Blumenschein, GR, Buzdar, AU, Legha, SS, Gutterman, JU, Hersh, EM & Bodey, GP 1980, 'Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine', Cancer Treatment Reports, vol. 64, no. 1, pp. 157-159.
Hortobagyi, G. N. ; Yap, H. Y. ; Wiseman, C. L. ; Blumenschein, G. R. ; Buzdar, A. U. ; Legha, S. S. ; Gutterman, J. U. ; Hersh, Evan M ; Bodey, G. P. / Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine. In: Cancer Treatment Reports. 1980 ; Vol. 64, No. 1. pp. 157-159.
@article{6ec98ca5a9774b95a35d9e9773110787,
title = "Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine",
abstract = "Moderate doses of methotrexate and L-asparaginase were added to standard doses of 5-fluorouracil, Adriamycin, and cyclophosphamide in an attempt to improve the overall response rate and survival following chemotherapy. In addition, nonspecific immunotherapy with either Corynebacterium parvum or Pseudomonas vaccine was integrated into this prospective randomized clinical trial. The overall toxicity (degree of granulocytopenia and thrombocytopenia, length of myelosuppression, and incidence of myelosuppression-related infection and infectious deaths) increased considerably and led to the termination of patient accrual. The incidence of stomatitis and diarrhea was also increased with the addition of methotrexate and L-asparaginase, and apparently was potentiated by the addition of Pseudomonas vaccine to this five-drug combination.",
author = "Hortobagyi, {G. N.} and Yap, {H. Y.} and Wiseman, {C. L.} and Blumenschein, {G. R.} and Buzdar, {A. U.} and Legha, {S. S.} and Gutterman, {J. U.} and Hersh, {Evan M} and Bodey, {G. P.}",
year = "1980",
language = "English (US)",
volume = "64",
pages = "157--159",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine

AU - Hortobagyi, G. N.

AU - Yap, H. Y.

AU - Wiseman, C. L.

AU - Blumenschein, G. R.

AU - Buzdar, A. U.

AU - Legha, S. S.

AU - Gutterman, J. U.

AU - Hersh, Evan M

AU - Bodey, G. P.

PY - 1980

Y1 - 1980

N2 - Moderate doses of methotrexate and L-asparaginase were added to standard doses of 5-fluorouracil, Adriamycin, and cyclophosphamide in an attempt to improve the overall response rate and survival following chemotherapy. In addition, nonspecific immunotherapy with either Corynebacterium parvum or Pseudomonas vaccine was integrated into this prospective randomized clinical trial. The overall toxicity (degree of granulocytopenia and thrombocytopenia, length of myelosuppression, and incidence of myelosuppression-related infection and infectious deaths) increased considerably and led to the termination of patient accrual. The incidence of stomatitis and diarrhea was also increased with the addition of methotrexate and L-asparaginase, and apparently was potentiated by the addition of Pseudomonas vaccine to this five-drug combination.

AB - Moderate doses of methotrexate and L-asparaginase were added to standard doses of 5-fluorouracil, Adriamycin, and cyclophosphamide in an attempt to improve the overall response rate and survival following chemotherapy. In addition, nonspecific immunotherapy with either Corynebacterium parvum or Pseudomonas vaccine was integrated into this prospective randomized clinical trial. The overall toxicity (degree of granulocytopenia and thrombocytopenia, length of myelosuppression, and incidence of myelosuppression-related infection and infectious deaths) increased considerably and led to the termination of patient accrual. The incidence of stomatitis and diarrhea was also increased with the addition of methotrexate and L-asparaginase, and apparently was potentiated by the addition of Pseudomonas vaccine to this five-drug combination.

UR - http://www.scopus.com/inward/record.url?scp=0018863415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018863415&partnerID=8YFLogxK

M3 - Article

C2 - 6991103

AN - SCOPUS:0018863415

VL - 64

SP - 157

EP - 159

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 1

ER -